Renalytix Plc ADR (NASDAQ: RNLX) closed the day trading at $0.86 down -5.49% from the previous closing price of $0.91. In other words, the price has decreased by -$0.0500 from its previous closing price. On the day, 378568 shares were traded.
Ratios:
For a better understanding of RNLX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.59 and its Current Ratio is at 0.59.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 18, 2022, initiated with a Buy rating and assigned the stock a target price of $30.
On January 04, 2022, BTIG Research started tracking the stock assigning a Buy rating and target price of $24.
On October 04, 2021, Guggenheim started tracking the stock assigning a Buy rating and target price of $28.Guggenheim initiated its Buy rating on October 04, 2021, with a $28 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNLX now has a Market Capitalization of 53.00M and an Enterprise Value of 54.65M. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.83. Its current Enterprise Value per Revenue stands at 22.68 whereas that against EBITDA is -1.48.
Stock Price History:
Over the past 52 weeks, RNLX has reached a high of $4.04, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 0.7399, while the 200-Day Moving Average is calculated to be 1.4776.
Shares Statistics:
Over the past 3-months, RNLX traded about 1.96M shares per day on average, while over the past 10 days, RNLX traded about 296.33k shares per day. A total of 46.89M shares are outstanding, with a floating share count of 46.30M. Shares short for RNLX as of Mar 15, 2024 were 894.62k with a Short Ratio of 0.46, compared to 1.27M on Feb 15, 2024.
Earnings Estimates
Current recommendations for the stock of the company come from 2 analysts. On average, analysts expect EPS of -$0.07 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.09, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.06 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.31 and -$0.37 for the fiscal current year, implying an average EPS of -$0.34. EPS for the following year is -$0.27, with 2 analysts recommending between -$0.27 and -$0.28.
Revenue Estimates
2 analysts predict $950k in revenue for the current quarter. It ranges from a high estimate of $1.1M to a low estimate of $800k. As of the current estimate, Renalytix Plc ADR’s year-ago sales were $724k, an estimated increase of 31.20% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $1.45M, an increase of 179.90% over than the figure of $31.20% in the same quarter last year. There is a high estimate of $1.6M for the next quarter, whereas the lowest estimate is $1.3M.
A total of 2 analysts have provided revenue estimates for RNLX’s current fiscal year. The highest revenue estimate was $4M, while the lowest revenue estimate was $3.2M, resulting in an average revenue estimate of $3.6M. In the same quarter a year ago, actual revenue was $3.4M, up 5.80% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $16.05M in the next fiscal year. The high estimate is $18M and the low estimate is $14.1M. The average revenue growth estimate for next year is up 345.80% from the average revenue estimate for this year.
